Shattuck Labs IncNASDAQ:STTK
- LAST PRICE10.5900
- TODAY'S CHANGE (%)0.8100 (8.2822%)
- Bid / Lots10.5900/ 2
- Ask / Lots12.1300/ 1
- Open / Previous Close9.8200 / 9.7800
- Day Range
- 52 Week Range
- Volume381,467
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | STTK |
|---|---|---|
| 09:32 ET | 5151 | 10.065 |
| 09:34 ET | 400 | 9.9605 |
| 09:36 ET | 8100 | 9.9 |
| 09:38 ET | 706 | 9.78 |
| 09:39 ET | 2500 | 9.8 |
| 09:41 ET | 300 | 9.96 |
| 09:45 ET | 100 | 10.03 |
| 09:50 ET | 100 | 10 |
| 09:52 ET | 1501 | 10 |
| 09:54 ET | 600 | 9.975 |
| 09:57 ET | 300 | 10 |
| 09:59 ET | 600 | 9.995 |
| 10:01 ET | 200 | 10 |
| 10:03 ET | 775 | 10.01 |
| 10:08 ET | 300 | 10 |
| 10:10 ET | 100 | 9.985 |
| 10:12 ET | 300 | 10 |
| 10:14 ET | 900 | 9.98 |
| 10:15 ET | 200 | 10 |
| 10:17 ET | 600 | 10 |
| 10:19 ET | 1000 | 9.97 |
| 10:21 ET | 400 | 10 |
| 10:24 ET | 800 | 9.91 |
| 10:28 ET | 222 | 9.91 |
| 10:30 ET | 900 | 10 |
| 10:32 ET | 200 | 9.975 |
| 10:33 ET | 1400 | 9.99 |
| 10:35 ET | 900 | 9.98 |
| 10:37 ET | 400 | 10 |
| 10:39 ET | 600 | 9.99 |
| 10:42 ET | 100 | 9.965 |
| 10:44 ET | 100 | 9.98 |
| 10:46 ET | 400 | 10.01 |
| 10:48 ET | 7572 | 10.1 |
| 10:50 ET | 10004 | 10.09 |
| 10:51 ET | 9238 | 10.16 |
| 10:53 ET | 9873 | 10.13 |
| 10:55 ET | 600 | 10.12 |
| 10:57 ET | 1006 | 10.13 |
| 11:00 ET | 200 | 10.09 |
| 11:02 ET | 200 | 10.1 |
| 11:04 ET | 851 | 10.085 |
| 11:06 ET | 400 | 10.13 |
| 11:09 ET | 700 | 10.03 |
| 11:11 ET | 400 | 10.035 |
| 11:13 ET | 200 | 10.01 |
| 11:15 ET | 9500 | 10.01 |
| 11:24 ET | 100 | 9.98 |
| 11:26 ET | 200 | 9.979 |
| 11:27 ET | 200 | 9.99 |
| 11:29 ET | 700 | 10.01 |
| 11:38 ET | 700 | 9.99 |
| 11:40 ET | 500 | 10.01 |
| 11:42 ET | 300 | 10 |
| 11:45 ET | 200 | 10 |
| 11:49 ET | 1640 | 10 |
| 11:51 ET | 500 | 10.005 |
| 11:56 ET | 1100 | 10 |
| 11:58 ET | 100 | 10.005 |
| 12:00 ET | 4000 | 10.12 |
| 12:02 ET | 215 | 10.075 |
| 12:03 ET | 3650 | 10.16 |
| 12:05 ET | 3387 | 10.17 |
| 12:07 ET | 2788 | 10.22 |
| 12:09 ET | 4500 | 10.26 |
| 12:12 ET | 840 | 10.2494 |
| 12:14 ET | 1780 | 10.2 |
| 12:16 ET | 400 | 10.1941 |
| 12:18 ET | 1900 | 10.11 |
| 12:20 ET | 199 | 10.11 |
| 12:21 ET | 100 | 10.09 |
| 12:23 ET | 408 | 10.09 |
| 12:27 ET | 400 | 10.12 |
| 12:30 ET | 1440 | 10.13 |
| 12:32 ET | 1499 | 10.19 |
| 12:34 ET | 100 | 10.175 |
| 12:36 ET | 6513 | 10.25 |
| 12:38 ET | 900 | 10.25 |
| 12:39 ET | 300 | 10.2 |
| 12:41 ET | 771 | 10.24 |
| 12:50 ET | 200 | 10.23 |
| 12:52 ET | 250 | 10.2 |
| 12:54 ET | 100 | 10.22 |
| 12:57 ET | 491 | 10.24 |
| 12:59 ET | 5287 | 10.3 |
| 01:01 ET | 1858 | 10.29 |
| 01:03 ET | 200 | 10.28 |
| 01:06 ET | 100 | 10.275 |
| 01:08 ET | 200 | 10.28 |
| 01:12 ET | 300 | 10.3 |
| 01:14 ET | 12092 | 10.3751 |
| 01:15 ET | 4050 | 10.37 |
| 01:17 ET | 480 | 10.365 |
| 01:19 ET | 712 | 10.33 |
| 01:21 ET | 1613 | 10.34 |
| 01:24 ET | 100 | 10.305 |
| 01:26 ET | 200 | 10.305 |
| 01:28 ET | 200 | 10.33 |
| 01:30 ET | 100 | 10.305 |
| 01:32 ET | 12138 | 10.4 |
| 01:33 ET | 626 | 10.38 |
| 01:37 ET | 423 | 10.3437 |
| 01:39 ET | 2700 | 10.355 |
| 01:42 ET | 4039 | 10.4 |
| 01:44 ET | 1500 | 10.44 |
| 01:46 ET | 100 | 10.4322 |
| 01:48 ET | 5728 | 10.455 |
| 01:50 ET | 206 | 10.46 |
| 01:51 ET | 3300 | 10.4799 |
| 01:55 ET | 600 | 10.4 |
| 01:57 ET | 2000 | 10.41 |
| 02:00 ET | 1600 | 10.3848 |
| 02:02 ET | 926 | 10.3 |
| 02:06 ET | 200 | 10.345 |
| 02:08 ET | 100 | 10.38 |
| 02:09 ET | 100 | 10.39 |
| 02:11 ET | 100 | 10.365 |
| 02:13 ET | 337 | 10.41 |
| 02:15 ET | 500 | 10.41 |
| 02:26 ET | 100 | 10.41 |
| 02:29 ET | 4544 | 10.36 |
| 02:31 ET | 400 | 10.355 |
| 02:33 ET | 220 | 10.33 |
| 02:38 ET | 500 | 10.3 |
| 02:42 ET | 100 | 10.325 |
| 02:44 ET | 496 | 10.34 |
| 02:45 ET | 200 | 10.355 |
| 02:47 ET | 300 | 10.36 |
| 02:51 ET | 100 | 10.36 |
| 02:54 ET | 300 | 10.355 |
| 02:56 ET | 600 | 10.36 |
| 02:58 ET | 400 | 10.38 |
| 03:00 ET | 300 | 10.41 |
| 03:03 ET | 100 | 10.38 |
| 03:05 ET | 200 | 10.38 |
| 03:07 ET | 200 | 10.39 |
| 03:09 ET | 1764 | 10.44 |
| 03:12 ET | 1360 | 10.44 |
| 03:14 ET | 423 | 10.44 |
| 03:16 ET | 500 | 10.4542 |
| 03:18 ET | 1850 | 10.4531 |
| 03:20 ET | 200 | 10.46 |
| 03:21 ET | 600 | 10.46 |
| 03:23 ET | 400 | 10.4513 |
| 03:25 ET | 600 | 10.46 |
| 03:27 ET | 500 | 10.465 |
| 03:30 ET | 10388 | 10.44 |
| 03:34 ET | 1400 | 10.415 |
| 03:36 ET | 1229 | 10.4 |
| 03:38 ET | 22998 | 10.415 |
| 03:39 ET | 2263 | 10.48 |
| 03:41 ET | 11629 | 10.6 |
| 03:43 ET | 154 | 10.5744 |
| 03:45 ET | 5043 | 10.56 |
| 03:48 ET | 3919 | 10.5899 |
| 03:50 ET | 200 | 10.56 |
| 03:52 ET | 3060 | 10.57 |
| 03:54 ET | 1870 | 10.5811 |
| 03:56 ET | 13852 | 10.6129 |
| 03:57 ET | 3108 | 10.62 |
| 03:59 ET | 18310 | 10.59 |
Apr 9, 2024
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024, from 4:05PM ET on Tuesday Apr 09, 2024 by Dow Jones
4:05PM ET on Tuesday Apr 09, 2024 by Dow JonesDJ Shattuck Labs Price Target Maintained With a $12.00/Share by Needham, from 6:27AM ET on Tuesday Apr 09, 2024 by Dow Jones
6:27AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 1, 2024
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference, from 7:00AM ET on Monday Apr 01, 2024 by Dow Jones
7:00AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Shattuck Labs Inc | 464.3M | -5.2x | --- |
Humacyte Inc | 464.4M | -3.7x | --- |
IGM Biosciences Inc | 449.7M | -2.0x | --- |
Nkarta Inc | 478.7M | -2.9x | --- |
Celcuity Inc | 480.2M | -5.9x | --- |
Fulcrum Therapeutics Inc | 441.6M | -4.5x | --- |
Company Information
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Contact Information
- Headquarters
- 500 W. 5Th Street, Suite 100AUSTIN, TX, United States 78701
- Phone
- 512-900-4690
- Fax
- ---
Executives
- Independent Chairman of the Board
- George Golumbeski
- Chief Executive Officer, Co-Founder, Director
- Taylor Schreiber
- Chief Financial Officer
- Andrew Neill
- Deputy General Counsel, Vice President - Intellectual Property
- Stephen Stout
- Chief Business Officer
- Casi Deyoung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $464.3M |
|---|---|
Revenue (TTM) | $1.7M |
Shares Outstanding | 47.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.06 |
EPS | $-2.05 |
Book Value | $3.06 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | 280.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,549.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
